# US 5,707,815 A · Mammalian monocyte chemoattractant protein receptors and assays using them > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,707,815 A - Document ID: US5707815A - Status: Granted - Kind: A - Application number: 08/450,393 - Filed: 1995-05-25 - Granted: 1998-01-13 - Earliest claimed: 1994-01-13 - Assignees: The Regents of the University of California - Inventors: Israel F. Charo; Shaun R. Coughlin - Web page: https://patentgrep.com/patent/US5707815A ## CPC - C07K 14/7158: {for chemokines} - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - A61P 11/00: Drugs for disorders of the respiratory system - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 35/00: Antineoplastic agents - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Novel human chemokine receptors, MCP-1RA and MCP-1RB, and processes for producing them are disclosed. The receptors, which are alternately spliced versions of MCP-1 receptor protein may be used in an assay to identify antagonists of MCP-1 which are therapeutically useful in the treatment of atherosclerosis and other diseases characterized by monocytic infiltrates. ## Claims ### Claim 1 A heterologous polypeptide produced by expression of a heterologous nucleic acid in a host cell, wherein said polypeptide comprises an amino acid sequence identical to the sequence of the extracellular amino terminal domain of a mammalian MCP-1 receptor, wherein said receptor is encoded by a cDNA which is present in a mammalian library and which will hybridize under stringent conditions with a probe having the nucleotide sequence of the complement of the coding sequence shown in SEQ ID No. 1 or SEQ ID No. 3. ### Claim 2 (depends on 1) The polypeptide of claim 1, wherein said MCP-1 receptor has the amino acid sequence of SEQ ID No. 2 or SEQ ID No. 4. ### Claim 3 (depends on 1) The heterologous polypeptide of claim 1, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 2. ### Claim 4 (depends on 1) The heterologous polypeptide of claim 1, wherein said polypeptide consists of the arnino acid sequence of SEQ ID NO: 4. ### Claim 5 (depends on 1) A heterologous polypeptide according to claim 1, wherein said MCP-1 receptor is a human receptor. ### Claim 6 An isolated polypeptide comprising the amino acid sequence of the extracellular amino terminal domain of a mammalian MCP-1 receptor, wherein said receptor is encoded by a cDNA which is present in a mammalian library and which will hybridize under stringent conditions with a probe having the nucleotide sequence of the complement of the coding sequence shown in SEQ ID NO. 1 or SEQ ID No. 3. ### Claim 7 (depends on 6) An isolated polypepfidc according to claim 6, wherein said MCP-1 receptor is a human receptor. ### Claim 8 An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 2 (FIG. 1) or SEQ ID NO: 4 (FIG. 2). ### Claim 9 (depends on 8) The isolated polypeptide of claim 8, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 2 (FIG. 1). ### Claim 10 (depends on 8) The isolated polypeptide of claim 8, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 4 (FIG. 2). ### Claim 11 (depends on 9) The isolated polypeptide of claim 9, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 2 (FIG. 1). ### Claim 12 (depends on 10) The isolated polypeptide of claim 10, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 4 (FIG. 2). ### Claim 13 An isolated immunogenic polypeptide comprising a fragment of SEQ ID No: 2 or SEQ ID No: 4, wherein said fragment has the amino acid sequence of an extracellular domain of MCP-1RA, substantially as shown in FIGS. 4A and 4B. ### Claim 14 (depends on 1, 2, 3) A method for identifying a substance that competes for MCP-1 receptor binding, comprising: contacting the polypeptide of any one of claims 1, 2, 3, or 4 with monocyte chemoattractant protein-1 (MCP-1) and various concentrations of a compound, assaying the specific binding to said polypeptide as a function of the concentration of said compound, and determining whether said compound affects said specific binding. ### Claim 15 (depends on 14) The method of claim 14, wherein said MCP-1 further comprises a label. ### Claim 16 (depends on 15) The method of claim 15, wherein said label is .sup.125 I. ### Claim 17 (depends on 6) A method for identifying a substance that competes for MCP-1 receptor binding, comprising: contacting the polypeptide of claim 6 with monocyte chemoattractant protein-1 (MCP-1) and various concentrations of a compound, assaying the specific binding to said polypeptide as a function of the concentration of said compound, and determining whether said compound affects said specific binding.